AstraZeneca buys FDA priority review voucher from Sobi

Last June, Alexion used its own PRV for its rare blood disorder therapy ravulizumab, a follow-up to Soliris which is already approved in the same indication.

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

This involved an acute kidney injury, haemolysis, and reduced platelet count and required hospitalisation in intensive care, dialysis and treatment with Alexion’s kidney drug Soliris (eculizumab).

Alexion's Soliris adds new approval in rare disease NMOSD

First ever drug approved for rare autoimmune disease. Alexion has gained a new FDA approved used for its rare disease blockbuster Soliris. ... Soliris will nevertheless still face competition in the coming years from new challengers from the likes of

The trials and tribulations of rare opportunities

Those hoping to follow where Humira, Soliris and Fabrazyme led should be prepared for clinical development to be complex. ... Humira, the world’s best-selling drug, has multiple orphan designations. Likewise Soliris (eculizomab) – which generated

1 2 3 4 5 6 7 [ Next 5 results ]